The lawsuit, filed by Bleichmar Fonti & Auld LLP, alleges that GRAIL and its senior executives misled shareholders regarding the viability of its flagship early-detection test. While the company touted the NHS-Galleri trial as a path toward national implementation, the complaint asserts that the three-year study design was fundamentally insufficient to meet its primary endpoint of reducing late-stage cancer diagnoses.

Market confidence evaporated on February 20, 2026, when GRAIL disclosed that the trial failed to demonstrate a statistically significant reduction in Stage III-IV cancers. Although the company suggested that a longer follow-up period might be necessary for future success, the immediate fallout saw share prices plummet from $101.53 to $50.21. The litigation, captioned Robbins v. GRAIL, Inc., et al., claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, arguing that management misrepresented the real-world efficacy of the Galleri test during the screening process.